Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive tracer reveals how experimental drug BI 3034701 leaves the body

NCT ID NCT07708493

Not yet recruiting Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase trial investigates how healthy male volunteers process and eliminate a single dose of the experimental drug BI 3034701. Eight men with normal weight or overweight will receive the drug mixed with a tiny amount of radioactive tracer, allowing researchers to track its path through urine, feces, and breath. The goal is to understand the drug's metabolism and how completely it is removed from the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called BI 3034701 mixed with a radioactive tracer
What this could lead to
If successful, this study will show how the body absorbs, breaks down, and gets rid of BI 3034701, which is needed before testing it as a treatment.
What could go wrong
This is a very early, small study in just 8 healthy men, so results may not predict how the drug works in sick people or at different doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.